Sugi Predict

Sugi Predict / Compounds / SCHEMBL820890

SCHEMBL820890

SCHEMBL820890

CC(C)(C)[Si](C)(C)O[C@@H]1C[C@@H](C(=O)O)N(C(=O)OCc2ccccc2)C1

nearest known ligand 0.46

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 1/20 0.43
▸ PDK1 Q15118 1/20 0.43
▸ PDK2 Q15119 1/20 0.43
▸ PDK3 Q15120 1/20 0.43
▸ PDK4 Q16654 1/20 0.43
▸ AGTR2 P50052 3/20 0.42
▸ NPC1 O15118 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ SMN1; SMN2 Q16637 1/20 0.41
▸ PREP P48147 2/20 0.41
▸ HTR2C P28335 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7488827 1.00 POLB (0.43) POLBPDK1PDK2PDK3PDK4
SCHEMBL7131978 1.00 POLB (0.43) POLBPDK1PDK2PDK3PDK4
SCHEMBL7122244 1.00 POLB (0.43) POLBPDK1PDK2PDK3PDK4
SCHEMBL819549 1.00 POLB (0.43) POLBPDK1PDK2PDK3PDK4
SCHEMBL19132495 0.93 POLB (0.43) POLBPDK1PDK2PDK3PDK4
SCHEMBL29993610 0.93 POLB (0.45) POLBPDK1PDK2PDK3PDK4
SCHEMBL29830276 0.93 POLB (0.45) POLBPDK1PDK2PDK3PDK4
SCHEMBL20666655 0.91 POLB (0.43) POLBPDK1PDK2PDK3PDK4
SCHEMBL9640980 0.91 POLB (0.43) POLBPDK1PDK2PDK3PDK4
SCHEMBL28747 0.91 POLB (0.43) POLBPDK1PDK2PDK3PDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11951147-B2 SMAC mimetic MEDIVIR AB (SE) 2024-04-09 — — US disclosed
US-20230149500-A1 SMAC MIMETIC MEDIVIR AB (SE) 2023-05-18 — — US disclosed
US-20230149500-A1 SMAC MIMETIC MEDIVIR AB (SE) 2023-05-18 — — US disclosed
CN-108440507-B Compound as apoptosis protein inhibitor and application thereof 南京圣和药物研发有限公司 2022-10-18 — — CN disclosed
US-11351221-B2 SMAC mimetic MEDIVIR AB (SE) 2022-06-07 — — US disclosed
US-10034912-B2 SMAC Mimetic TetraLogic Birinapant UK Ltd. (GB) 2018-07-31 — — US disclosed
US-20170182116-A1 SMAC Mimetic MEDIVIR AB (SE) 2017-06-29 — — US disclosed
US-20170182116-A1 SMAC Mimetic MEDIVIR AB (SE) 2017-06-29 — — US disclosed
US-20150158908-A1 SMAC Mimetic for Treating Myelodysplastic Syndromes TETRALOGIC BIRINAPANT UK LTD (GB) 2015-06-11 — — US disclosed
US-20150158908-A1 SMAC Mimetic for Treating Myelodysplastic Syndromes TETRALOGIC BIRINAPANT UK LTD (GB) 2015-06-11 — — US disclosed
US-20140243276-A1 SMAC MIMETIC (BIRINAPANT) FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES (CANCER) TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2014-08-28 — — US disclosed
US-20140073579-A1 SMAC Mimetic TETRALOGIC PHARMACEUTICALS CORP. (US) 2014-03-13 — — US disclosed
WO-2013049350-A1 SMAC MIMETIC (BIRINAPANT) FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES (CANCER) TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2013-04-04 — — WO disclosed
US-20130012564-A1 SMAC Mimetic TETRALOGIC PHARMACEUTICALS CORP. (US) 2013-01-10 — — US disclosed
US-20130012564-A1 SMAC Mimetic TETRALOGIC PHARMACEUTICALS CORP. (US) 2013-01-10 — — US disclosed
US-8283372-B2 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic TETRALOGIC PHARMACEUTICALS CORP. (US) 2012-10-09 — — US disclosed
US-20120115922-A1 SMAC MIMETEC MEDIVIR AB (SE) 2012-05-10 — — US disclosed
US-20110288116-A1 IAP INHIBITORS TETRALOGIC PHARMACEUITCAL CORPORATION (US) 2011-11-24 — — US disclosed
US-20110003877-A1 SMAC Mimetic TETRALOGIC PHARMACEUTICALS CORPORATION (US) 2011-01-06 — — US disclosed
US-7304165-B2 Oligomers and polymers of di-substituted cyclic imino carboxylic acids WISCONSIN ALUMNI RESEARCH FOUNDATION (US) 2007-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130012564-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 POLB 126/4885PDK1 3804/4885PDK2 3856/4885
US-20140243276-A1 SMAC MIMETIC (BIRINAPANT) FOR USE IN THE TREATMENT OF PROLIFERATIVE DISEASES (CANCER) BIRC5, BIRC3, BIRC7 POLB 196/4885PDK1 3134/4885PDK2 3339/4885
US-20150158908-A1 SMAC Mimetic for Treating Myelodysplastic Syndromes MCL1, MPL, THPO POLB 356/4885PDK1 3022/4885PDK2 3566/4885
US-20110003877-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 POLB 126/4885PDK1 3804/4885PDK2 3856/4885
US-20110288116-A1 IAP INHIBITORS XIAP, BIRC5, BIRC7 POLB 3282/4885PDK1 3157/4885PDK2 4548/4885
US-20170182116-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 POLB 126/4885PDK1 3806/4885PDK2 3857/4885
US-11951147-B2 SMAC mimetic SMARCC1, SMARCC2, MCL1 POLB 126/4885PDK1 3806/4885PDK2 3857/4885
US-10034912-B2 SMAC Mimetic SMARCC1, SMARCC2, MCL1 POLB 126/4885PDK1 3804/4885PDK2 3856/4885
US-20120115922-A1 SMAC MIMETEC SMARCC1, SMARCC2, SMARCE1 POLB 83/4885PDK1 4077/4885PDK2 4202/4885
US-20230149500-A1 SMAC MIMETIC SMARCC1, SMARCC2, MCL1 POLB 126/4885PDK1 3804/4885PDK2 3856/4885
US-11351221-B2 SMAC mimetic SMARCC1, SMARCC2, MCL1 POLB 126/4885PDK1 3806/4885PDK2 3857/4885
US-20140073579-A1 SMAC Mimetic SMARCC1, SMARCC2, MCL1 POLB 126/4885PDK1 3804/4885PDK2 3856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.